Experience with Ceftriaxone in the Treatment of Pulmonary Infections
DOI:
https://doi.org/10.5915/17-1-12717Keywords:
Ceftriaxone, Pulmonary Infection, cephalosporin, CefoxitinAbstract
DOI: http://dx.doi.org/10.5915/17-1-12717
This paper describes the experience with a new third generation cephalosporin, Ceftriaxone, in the treatment of 60 patients with bacterial pulmonary infection. The unique pharmacokinetics of Ceftriaxone allow its usage twice a day in contrast to the 4 to 6 times a day for comparable antibiotics, with potential cost savings. Administered twice a day the overall cure rate was 94% with no serious side effects. A brief review of the clinical application of Cephalosporins in the treatment of infections is included.
Presented at the 17th Annual Convention of the Islamic Medical
Association in St. Louis, Missouri, August 10-12, 1984
Downloads
Published
1985-01-12
Issue
Section
Original Articles
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).